AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17251874 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 389
Study 17251874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 14992907 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible perfusion system (n = 19)
Number of subjects: 40
Study 14992907 — intervention group
Group type: COMPARATOR
Intervention: Conventional perfusion system (n = 21)
Number of subjects: 40
Study 11355409 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed primer pairs for STR typing (HUMFES, HUMTH01, HUMTPOX)
Number of subjects: 0
Study 11355409 — intervention group
Group type: COMPARATOR
Intervention: Commonly used primer pairs for STR typing
Number of subjects: 0
Study 9300992 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo tracking of digitized radiofrequency ultrasound
Number of subjects: 26
Study 9300992 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode imaging with automated edge detection
Number of subjects: 26
Study 9300992 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode imaging with automated edge detection
Number of subjects: 26
Study 9300992 — intervention group
Group type: COMPARATOR
Intervention: Echo tracking
Number of subjects: 26
Study 9300992 — intervention group
Group type: COMPARATOR
Intervention: B-mode imaging
Number of subjects: 26
Study 9300992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier series model and cubic smoothing spline
Number of subjects: 26
Study 8064171 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic preparation (Kwai)
Number of subjects: 415
Study 8064171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 3120557 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 105
Study 3120557 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine associated with cytoprotective drugs (pirenzepine or rosaprostol)
Number of subjects: 105
Study 3120557 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine associated with anti-H2 receptor antagonists (ranitidine or famotidine)
Number of subjects: 105
Study 3120557 — intervention group
Group type: COMPARATOR
Intervention: Blind placebo
Number of subjects: 105
Study 29325663 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone self-monitoring during a 6-month weight loss trial
Number of subjects: 31
Study 27120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted patient adherence intervention
Number of subjects: 132
Study 27120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview-based provider intervention
Number of subjects: 132
Study 27120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 132
Study 25636808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) adherence intervention including personalized dietary‐nutritional education, Web 2.0 approach, and group sessions for 2 years.
Number of subjects: 0
Study 25636808 — intervention group
Group type: COMPARATOR
Intervention: Usual diet with general nutritional counselling (Control group).
Number of subjects: 0
Study 23040886 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4)
Number of subjects: 83
Study 23040886 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 83
Study 23040886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (LTD4 and methacholine)
Number of subjects: 83
Study 21108739 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleMedicine intervention
Number of subjects: 17
Study 21108739 — intervention group
Group type: COMPARATOR
Intervention: Physician visit (Control)
Number of subjects: 17
Study 18349597 — intervention group
Group type: COMPARATOR
Intervention: Mesotherapy (mixed solution of aminophylline, buflomedil, and lidocaine) injected weekly into the superficial dermis of one thigh for 12 weeks.
Number of subjects: 20
Study 18349597 — intervention group
Group type: COMPARATOR
Intervention: Mesotherapy (mixed solution of aminophylline, buflomedil, and lidocaine)
Number of subjects: 20
Study 12506176 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent bolus cisplatin with radiation (arm B)
Number of subjects: 295
Study 12506176 — intervention group
Group type: EXPERIMENTAL
Intervention: Split course of radiation with concurrent infusional fluorouracil and bolus cisplatin (arm C)
Number of subjects: 295
Study 12506176 — intervention group
Group type: COMPARATOR
Intervention: Single daily fractionated radiation (arm A, control)
Number of subjects: 295
Study 9609273 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910
Number of subjects: 1780
Study 9609273 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 1780
Study 8570343 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort group (maximum arm-cuff pressure of 280 mmHg)
Number of subjects: 46
Study 8570343 — intervention group
Group type: COMPARATOR
Intervention: Control group (maximum arm-cuff pressure of 160 mmHg)
Number of subjects: 46
Study 2203397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin during streptokinase infusion (group 1)
Number of subjects: 37
Study 2203397 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin after streptokinase infusion (group 2)
Number of subjects: 37
Study 367716 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine skin graft
Number of subjects: 28
Study 367716 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze (control)
Number of subjects: 28
Study 31531771 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Streptococcus dentisani (n=5)
Number of subjects: 11
Study 31531771 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of Streptococcus dentisani for a week (n=6)
Number of subjects: 11
Study 31531771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing schedules of Streptococcus dentisani
Number of subjects: 11
Study 31064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Information given in labour only, written format
Number of subjects: 49
Study 31064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Information in labour, verbal
Number of subjects: 49
Study 31064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Information at 36 weeks plus labour, written
Number of subjects: 49
Study 31064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Information at 36 weeks plus labour, verbal
Number of subjects: 49
Study 31064263 — intervention group
Group type: COMPARATOR
Intervention: Information only during labour
Number of subjects: 49
Study 28093815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (NSO) 500 mg twice daily for 4 weeks
Number of subjects: 80
Study 28093815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25972454 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Number of subjects: 54
Study 25972454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22886724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure (0.24 T static magnetic stray field and 0.49 T·s(‐1) time‐varying magnetic field)
Number of subjects: 30
Study 22886724 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure (0.37 T static magnetic stray field and 0.70 T·s(‐1) time‐varying magnetic field)
Number of subjects: 30
Study 22886724 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 30
Study 22886724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem task exposure (all conditions)
Number of subjects: 30
Study 21285160 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIO-469 30 mg IR
Number of subjects: 302
Study 21285160 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIO-469 60 mg IR
Number of subjects: 302
Study 21285160 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIO-469 100 mg ER
Number of subjects: 302
Study 21285160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 19965037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telemonitoring
Number of subjects: 137
Study 19965037 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study 17454917 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk smoking status
Number of subjects: 217
Study 17454917 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 217
Study 17454917 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores of emotional distress
Number of subjects: 217
Study 17454917 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 217
Study 17454917 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 217
Study 17454917 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational factors
Number of subjects: 217
Study 14736573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administered by patch (3.5 mg for low-hostility non-smokers, 21 mg for high-hostility smokers)
Number of subjects: 86
Study 14736573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administered by patch (21 mg)
Number of subjects: 86
Study 14736573 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral ratings
Number of subjects: 86
Study 11546969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Number of subjects: 70
Study 11546969 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical management
Number of subjects: 70
Study 9771059 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone pre-treatment
Number of subjects: 213
Study 9771059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 7825161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled omentum
Number of subjects: 64
Study 7825161 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic muscle transposition (latissimus dorsi, pectoralis major, serratus anterior, trapezius)
Number of subjects: 64
Study 2971186 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41740
Number of subjects: 0
Study 2971186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30206020 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 46
Study 28688787 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually customized power wheelchairs for 12 months
Number of subjects: 31
Study 26247543 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐WBI
Number of subjects: 287
Study 23860964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) at a dose of 2 × 10(6) cells/kg for each infusion twice a week for 4 weeks, with the option for weekly infusions for an additional 4 weeks if needed.
Number of subjects: 14
Study 21771568 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 21-28 days)
Number of subjects: 1960
Study 21771568 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1960
Study 21771568 — intervention group
Group type: COMPARATOR
Intervention: Clodronic acid
Number of subjects: 1960
Study 19155070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy (8 sessions)
Number of subjects: 373
Study 17200096 — intervention group
Group type: EXPERIMENTAL
Intervention: Body & Soul dietary intervention
Number of subjects: 0
Study 14722733 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene
Number of subjects: 56
Study 14722733 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (40 mg/day)
Number of subjects: 56
Study 14722733 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene and Tamoxifen
Number of subjects: 56
Study 11394918 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on cold pressor pain sensations
Number of subjects: 60
Study 11394918 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid cold pressor pain sensations
Number of subjects: 60
Study 11394918 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxiety sensitivity with avoidance instruction
Number of subjects: 60
Study 11394918 — intervention group
Group type: COMPARATOR
Intervention: Low anxiety sensitivity
Number of subjects: 60
Study 9593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chlorambucil
Number of subjects: 1535
Study 9593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chlorambucil plus prednisone
Number of subjects: 1535
Study 9593789 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group for first trial)
Number of subjects: 1535
Study 9593789 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group for second trial)
Number of subjects: 1535
Study 8147544 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (n = 293)
Number of subjects: 585
Study 8147544 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (n = 292)
Number of subjects: 585
Study 3058874 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week regimen of adjuvant chemotherapy
Number of subjects: 418
Study 3058874 — intervention group
Group type: COMPARATOR
Intervention: 36-week regimen of adjuvant chemotherapy
Number of subjects: 418
Study 30400876 — intervention group
Group type: EXPERIMENTAL
Intervention: STROKE-CARD intervention
Number of subjects: 2160
Study 30400876 — intervention group
Group type: COMPARATOR
Intervention: Usual post-stroke patient care (control)
Number of subjects: 2160
Study 29308522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 300mg, bid for 5 days after scaling and root planing (SRP)
Number of subjects: 20
Study 29308522 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent SRP only
Number of subjects: 20
Study 26094712 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 200
Study 26094712 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (nurse titrated analgesia)
Number of subjects: 200
Study 23035844 — intervention group
Group type: EXPERIMENTAL
Intervention: AC952 Aloe vera inner leaf gel powder
Number of subjects: 45
Study 23035844 — intervention group
Group type: EXPERIMENTAL
Intervention: UP780 Aloe vera inner leaf gel powder standardized with 2% aloesin
Number of subjects: 45
Study 23035844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20707253 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg plus codeine 60 mg tid for 24 hours (Group A)
Number of subjects: 60
Study 20707253 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 10 mg qid for 24 hours (Group B)
Number of subjects: 60
Study 18297251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 18297251 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-midazolam
Number of subjects: 20
Study 16488952 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-MMC (deep sclerectomy with intraoperative low dose mitomycin C 0.25 mg/ml for 2 minutes)
Number of subjects: 39
Study 16488952 — intervention group
Group type: COMPARATOR
Intervention: DS-noMMC (deep sclerectomy without mitomycin C)
Number of subjects: 39
Study 16488952 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-MMC
Number of subjects: 39
Study 16488952 — intervention group
Group type: COMPARATOR
Intervention: DS-noMMC
Number of subjects: 39
Study 15106284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin administered for 10 days
Number of subjects: 40
Study 15106284 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (corticosteroids, vasoactive agents, multivitamins, and anticoagulants)
Number of subjects: 40
Study 11102254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg bolus followed by 75 mg per day for 3-12 months) + Aspirin
Number of subjects: 12500
Study 11102254 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 12500
Study 11102254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Ticlopidine
Number of subjects: 12500
Study 11102254 — intervention group
Group type: COMPARATOR
Intervention: Thienopyridines (including Clopidogrel)
Number of subjects: 12500
Study 9108859 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 61
Study 9108859 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 61
Study 8258620 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia
Number of subjects: 10
Study 8258620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4062333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide injection
Number of subjects: 9
Study 4062333 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% betamethasone dipropionate under occlusion
Number of subjects: 9
Study 4062333 — intervention group
Group type: COMPARATOR
Intervention: Emollient under occlusion (Control)
Number of subjects: 9
Study 29665109 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-of-sight approach
Number of subjects: 110
Study 29665109 — intervention group
Group type: COMPARATOR
Intervention: Side approach
Number of subjects: 110
Study 29665109 — intervention group
Group type: EXPERIMENTAL
Intervention: APPLES mnemonic
Number of subjects: 110
Study 27068249 — intervention group
Group type: EXPERIMENTAL
Intervention: Total endoscopic ablation
Number of subjects: 36
Study 27068249 — intervention group
Group type: COMPARATOR
Intervention: Rate control therapy
Number of subjects: 36
Study 24816889 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body acute resistance exercise
Number of subjects: 34
Study 24816889 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body acute resistance exercise
Number of subjects: 34
Study 24816889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body acute resistance exercise
Number of subjects: 34
Study 24816889 — intervention group
Group type: COMPARATOR
Intervention: Control period (rest)
Number of subjects: 34
Study 21752556 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 106
Study 21752556 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education (WHE)
Number of subjects: 106
Study 20149955 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month group behavioral treatment designed to increase autonomy and self-regulation for weight control
Number of subjects: 239
Study 20149955 — intervention group
Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 239
Study 18855165 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT using (99m)Tc‐hexamethylpropyleneamine oxime (HMPAO)
Number of subjects: 24
Study 18855165 — intervention group
Group type: EXPERIMENTAL
Intervention: DSC‐MRI with gadobutrol formula
Number of subjects: 24
Study 18855165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no objective cognitive impairment)
Number of subjects: 24
Study 15807215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (n = 178)
Number of subjects: 330
Study 15807215 — intervention group
Group type: COMPARATOR
Intervention: Routine methods (Control group, n = 152)
Number of subjects: 330
Study 14671145 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist starting on day 1 of stimulation (n = 30)
Number of subjects: 60
Study 14671145 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist starting on day 6 of stimulation (n = 30)
Number of subjects: 60
Study 11192147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 11192147 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 0
Study 8636452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine diacetate gum (20 mg total daily)
Number of subjects: 151
Study 8636452 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 151
Study 8636452 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthwash (40 mg total daily)
Number of subjects: 151
Study 8636452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine diacetate gum
Number of subjects: 151
Study 8636452 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 151
Study 1452916 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 3534
Study 1452916 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 3534
Study 3909327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus clindamycin
Number of subjects: 73
Study 3909327 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus clindamycin
Number of subjects: 73
Study 31136658 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain rye bread (WGR)
Number of subjects: 15
Study 31136658 — intervention group
Group type: COMPARATOR
Intervention: Rye bran or wheat aleurone
Number of subjects: 15
Study 30643069 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation combined with biofeedback electrical stimulation treatment for 30 days
Number of subjects: 72
Study 30643069 — intervention group
Group type: COMPARATOR
Intervention: Manipulation therapy
Number of subjects: 72
Study 30643069 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation biofeedback therapy
Number of subjects: 72
Study 27396247 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block added to infraclavicular brachial plexus block
Number of subjects: 11
Study 27396247 — intervention group
Group type: COMPARATOR
Intervention: Control group (infraclavicular brachial plexus block only)
Number of subjects: 11
Study 24972190 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg tid for a mean of 36.6 days
Number of subjects: 11
Study 22783708 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Supreme
Number of subjects: 150
Study 22783708 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 150
Study 22783708 — intervention group
Group type: COMPARATOR
Intervention: LMA-ProSeal
Number of subjects: 150
Study 19563466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 479
Study 19563466 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 0.005% ointment
Number of subjects: 479
Study 17634259 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO (0.3 g x kg(‐1) protein hydrolysate)
Number of subjects: 7